Cardiff Oncology, Inc. (CRDF) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Cardiff Oncology, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Cardiff Oncology, Inc. interactive price chart and technical analysis...
Cardiff Oncology, Inc. (CRDF) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Cardiff Oncology, Inc. (Stock Symbol: CRDF)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 43 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $154 million - Classified as a
small-cap investment offering high growth potential.
Return on Equity (ROE): -26.8% -
Below-average
shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Cardiff Oncology, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Cardiff Oncology, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Cardiff Oncology, Inc. (CRDF) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cardiff Oncology, Inc. stock analysis.
Loading fundamental data...
Loading Cardiff Oncology, Inc. comprehensive fundamental analysis and insider trading data...
Deep dive into Cardiff Oncology, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Cardiff Oncology, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Cardiff Oncology, Inc.: With a P/E ratio of -4.00, the market sees the stock as potentially undervalued.
P/E Ratio-4.00x
P/B Ratio2.63x
Market Cap$154M
EPS$-0.87
Book Value/Share$0.88
Revenue/Share$0.01
FCF/Share$-1.04
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Cardiff Oncology, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Cardiff Oncology, Inc.: An ROE of -26.8% indicates room for improvement in shareholder value creation.
ROE-26.8%
ROA-25.4%
ROIC-26.7%
Operating Margin-1951.6%
Net Margin-2115.4%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Cardiff Oncology, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Cardiff Oncology, Inc.: A current ratio of 20.38 indicates strong liquidity.
Current Ratio20.38x
Quick Ratio19.48x
D/E Ratio0.02x
Financial Leverage1.07x
Interest Coverage-646.9x
Working Capital$127M
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Cardiff Oncology, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Cardiff Oncology, Inc.: Free cash flow of $-28M indicates cash challenges that need attention.
Operating Cash Flow$-27M
Free Cash Flow$-28M
FCF/Sales-749.7%
CapEx/Sales57.1%
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Cardiff Oncology, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Cardiff Oncology, Inc.: An asset turnover of 0.01x suggests room for improvement in asset utilization.
Asset Turnover0.01x
Receivables Turnover1.1x
Fixed Assets Turnover0.2x
Days Sales Outstanding348 days
Payables Period455 days
Understanding Financial Statement Data
What these metrics mean: Key figures from Cardiff Oncology, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Cardiff Oncology, Inc.:
Income Statement ($ Millions)
Operating Income$-159M
Net Income$-172M
R&D Expense$426M
SG&A Expense$750M
Balance Sheet Highlights ($ Millions)
Total Current Assets$98M
Cash & Short-term Investments$93M
Total Liabilities$7M
Short-term Debt$11M
Accounts Receivable$0M
Dividend & Shareholder Information
Shares Outstanding67M
Growth Metrics (YoY)
EPS Growth-21.9%
Latest Cardiff Oncology, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Cardiff Oncology, Inc. (CRDF) stock price and investment outlook.
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced ...
The new name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer with its development of onvansertib, a first-in-class, third-generation, oral and highly ...
SAN DIEGO, June 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for ...
--Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference ...
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...
Cardiff Oncology Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers ...
About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range ...
A look at the shareholders of Cardiff Oncology, Inc. (NASDAQ:CRDF) can tell us which group is most powerful. We can see that retail investors own the lion's share in the company with 49% ownership ...
Marshall Wace LLP trimmed its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) by 56.2% during the 4th quarter, HoldingsChannel reports. The firm owned 62,600 shares of ...
Cardiff Oncology announced initial data from the ongoing CRDF-004 trial in December, 2024. Additional clinical data from the trial is expected in 1H of 2025. About Cardiff Oncology, Inc.
Cardiff Oncology, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Cardiff Oncology, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Cardiff Oncology, Inc. Stock Forecast
How accurate are Cardiff Oncology, Inc. stock predictions?
Our AI model demonstrates 59% historical accuracy for CRDF predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Cardiff Oncology, Inc. stock price forecasts?
Is Cardiff Oncology, Inc. a good investment in 2025?
Based on our AI analysis, Cardiff Oncology, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Cardiff Oncology, Inc. forecasts updated?
Cardiff Oncology, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Cardiff Oncology, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Cardiff Oncology, Inc. stock.
